• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于结构的 CDK2 抑制剂设计及抗癌潜在先导化合物的发现。

Structure guided inhibitor designing of CDK2 and discovery of potential leads against cancer.

机构信息

Department of S & H (Computer Applications), Sathyabama University, Chennai, India.

出版信息

J Mol Model. 2013 Sep;19(9):3581-9. doi: 10.1007/s00894-013-1887-8. Epub 2013 Jun 1.

DOI:10.1007/s00894-013-1887-8
PMID:23728955
Abstract

On the basis of stereo specific information obtained from crystal structures of CDK2, indole and chromene analogues were designed by suitably substituting the pharmacophores on their moiety and docked with target protein for calculating binding affinities. The binding affinities are represented in glide score. (5E)-5-[(1-methyl-1H-indol-3-yl)methylidene]-2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide (I1), (5E)-5-(1H-indol-3-ylmethylidene)-2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide (I2) and 2-amino-4-(4-methyl phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (C9) were selected for synthesis and biological testing based on vital interactions. (5E)-5-(1H-indol-3-ylmethylidene)-2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide(I2) and 2-amino-4-(4-methyl phenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (C9) were proved to be active against MCF-7 and HeLa cell lines.

摘要

基于从 CDK2 的晶体结构中获得的立体特异性信息,通过适当取代其部分的药效团,设计了吲哚和色烯类似物,并与靶蛋白对接以计算结合亲和力。结合亲和力用 Glide 得分表示。(5E)-5-[(1-甲基-1H-吲哚-3-基)亚甲基]-2,4,6-三氧代四氢-2H-嘧啶-1-基)(I1)、(5E)-5-(1H-吲哚-3-基亚甲基)-2,4,6-三氧代四氢-2H-嘧啶-1-基)(I2)和 2-氨基-4-(4-甲基苯基)-5-氧代-5,6,7,8-四氢-4H-色烯-3-甲腈(C9)被选择用于合成和基于重要相互作用的生物测试。(5E)-5-(1H-吲哚-3-基亚甲基)-2,4,6-三氧代四氢-2H-嘧啶-1-基(I2)和 2-氨基-4-(4-甲基苯基)-5-氧代-5,6,7,8-四氢-4H-色烯-3-甲腈(C9)被证明对 MCF-7 和 HeLa 细胞系具有活性。

相似文献

1
Structure guided inhibitor designing of CDK2 and discovery of potential leads against cancer.基于结构的 CDK2 抑制剂设计及抗癌潜在先导化合物的发现。
J Mol Model. 2013 Sep;19(9):3581-9. doi: 10.1007/s00894-013-1887-8. Epub 2013 Jun 1.
2
Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.新型吡唑并吡啶、呋咱吡啶和吡啶衍生物作为 CDK2 抑制剂的发现:设计、合成、对接研究和抗增殖活性。
Molecules. 2021 Jun 26;26(13):3923. doi: 10.3390/molecules26133923.
3
An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.吡唑并[1,5-a]嘧啶类CDK2抑制剂相互作用机制的计算机模拟研究
Mol Biosyst. 2013 Sep;9(9):2266-81. doi: 10.1039/c3mb70186g.
4
Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.鉴定细胞周期蛋白依赖性激酶 2 的高亲和力抑制剂用于抗癌治疗。
Molecules. 2019 Dec 15;24(24):4589. doi: 10.3390/molecules24244589.
5
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.基于结构的细胞周期蛋白依赖性激酶2首个变构抑制剂的发现
Cell Cycle. 2014;13(14):2296-305. doi: 10.4161/cc.29295. Epub 2014 Jun 9.
6
Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.一些新型 4,6-二取代吡唑并[3,4-d]嘧啶作为细胞周期蛋白依赖性激酶 2 (CDK2) 抑制剂的合成、抗癌评价及分子对接研究。
Bioorg Chem. 2018 Sep;79:46-59. doi: 10.1016/j.bioorg.2018.02.030. Epub 2018 Mar 17.
7
New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.新型噻唑-腙-香豆素杂合体靶向人宫颈癌细胞:合成、CDK2 抑制、QSAR 和分子对接研究。
Bioorg Chem. 2019 May;86:80-96. doi: 10.1016/j.bioorg.2019.01.026. Epub 2019 Jan 19.
8
Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.2-苯胺基-4-(噻唑-5-基)嘧啶与CDK2和CDK7复合物结合选择性的分子模拟研究
Mol Biosyst. 2016 Jan;12(1):145-61. doi: 10.1039/c5mb00630a.
9
Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.通过三维定量构效关系(3D-QSAR)和分子动力学模拟对N-苯基嘧啶-2-胺对细胞周期蛋白依赖性激酶2(CDK2)和细胞周期蛋白依赖性激酶4(CDK4)的选择性进行表征的分子建模研究。
Mol Biosyst. 2016 Apr;12(4):1250-68. doi: 10.1039/c5mb00860c. Epub 2016 Feb 17.
10
Virtual screening and discovery of novel aurora kinase inhibitors.新型极光激酶抑制剂的虚拟筛选与发现
Curr Top Med Chem. 2014;14(17):2006-19. doi: 10.2174/1568026614666140929151140.

本文引用的文献

1
Identifying and characterizing binding sites and assessing druggability.识别和表征结合位点并评估成药性。
J Chem Inf Model. 2009 Feb;49(2):377-89. doi: 10.1021/ci800324m.
2
Cell cycle, CDKs and cancer: a changing paradigm.细胞周期、细胞周期蛋白依赖性激酶与癌症:不断变化的范式
Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602.
3
Xanthones with growth inhibition against HeLa cells from Garcinia xipshuanbannaensis.来自西双版纳藤黄具有对HeLa细胞生长抑制作用的呫吨酮类化合物。
Phytochemistry. 2008 Aug;69(11):2187-92. doi: 10.1016/j.phytochem.2008.05.019. Epub 2008 Jul 7.
4
New method for fast and accurate binding-site identification and analysis.快速准确识别和分析结合位点的新方法。
Chem Biol Drug Des. 2007 Feb;69(2):146-8. doi: 10.1111/j.1747-0285.2007.00483.x.
5
A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia.
Int J Gynecol Cancer. 2006 Mar-Apr;16(2):786-90. doi: 10.1111/j.1525-1438.2006.00386.x.
6
Homopterocarpanes as bridged triarylethylene analogues: synthesis and antagonistic effects in human MCF-7 breast cancer cells.作为桥连三芳基乙烯类似物的高异黄酮:在人MCF-7乳腺癌细胞中的合成及拮抗作用
Farmaco. 2005 Feb;60(2):135-47. doi: 10.1016/j.farmac.2004.09.006. Epub 2004 Dec 16.
7
Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells.吲哚 - 3 - 甲醇(I3C)可诱导前列腺癌细胞的细胞生长抑制、G1期细胞周期阻滞及凋亡。
Oncogene. 2001 May 24;20(23):2927-36. doi: 10.1038/sj.onc.1204365.
8
Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.吲哚 - 3 - 甲醇治疗宫颈上皮内瘤变的安慰剂对照试验。
Gynecol Oncol. 2000 Aug;78(2):123-9. doi: 10.1006/gyno.2000.5847.
9
Structure-based drug design.
Nature. 1996 Nov 7;384(6604 Suppl):23-6. doi: 10.1038/384023a0.
10
Protein structure--based drug design.基于蛋白质结构的药物设计。
Annu Rev Biophys Biomol Struct. 1994;23:349-75. doi: 10.1146/annurev.bb.23.060194.002025.